BioSpace News Archive

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS) today announced a productive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) following the Phase 2 data in episodic migraine previously released in October 2023, that supports advancing ABP-450 (prabotulinumtoxinA) injection into the proposed pivotal Phase 3 program.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, announced a 1-for-15 reverse stock split of its common stock.

Neogen Corporation will issue its third-quarter earnings release before the opening of the market on Tuesday, April 9, 2024.

VolitionRx Limited, a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Tivic Health® Systems, Inc. (“Tivic Health”) (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET.

Ecolab will host a live webcast of its first quarter earnings conference call to discuss 2024 first quarter results.

Personalis, Inc. announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and March 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under Personalis’ 2020 Inducement Plan.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

Tempo Therapeutics, Inc (“Tempo”) a leading innovator in tissue engineering and regenerative medicine, today announced the successful completion of its $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023.